Skip to main content

Table 6 Scenario analyses results for CAZ-AVI sequence vs. Meropenem sequence

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

ScenarioIncremental cost per QALY gained (% change from base case)
Base case€ 15,574
Resistance adjustments
 No adjustments€ 27,626 (+ 77%)
Second-line efficacy
 Assumed 100% response/cure rates in treatment€ 30,614 (+ 97%)
  1. CAZ-AVI = ceftazidime-avibactam; QALY = quality-adjusted life year.
  2. CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem. Ceftolozane/tazobactam sequence: Ceftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem